Search

Your search keyword '"Ishigo, Tomoyuki"' showing total 9 results
Start Over Author "Ishigo, Tomoyuki" Publisher wiley
9 results on '"Ishigo, Tomoyuki"'

2. Plasma amino acid profiling improves predictive accuracy of adverse events in patients with heart failure

Author

Kouzu, Hidemichi, primary, Katano, Satoshi, additional, Yano, Toshiyuki, additional, Ohori, Katsuhiko, additional, Nagaoka, Ryohei, additional, Inoue, Takuya, additional, Takamura, Yuhei, additional, Ishigo, Tomoyuki, additional, Watanabe, Ayako, additional, Koyama, Masayuki, additional, Nagano, Nobutaka, additional, Fujito, Takefumi, additional, Nishikawa, Ryo, additional, Ohwada, Wataru, additional, and Miura, Tetsuji, additional

Published
2021
Full Text
View/download PDF

3. Does renin‐angiotensin system inhibition have impacts on muscle mass and bone mineral density in heart failure patients?

Author

Katano, Satoshi, primary, Yano, Toshiyuki, additional, Shimizu, Masaki, additional, Ohori, Katsuhiko, additional, Kouzu, Hidemichi, additional, Koyama, Masayuki, additional, Nagaoka, Ryohei, additional, Inoue, Takuya, additional, Takamura, Yuhei, additional, Ishigo, Tomoyuki, additional, Takashima, Hiroyuki, additional, Katayose, Masaki, additional, Ohnishi, Hirofumi, additional, and Miura, Tetsuji, additional

Published
2021
Full Text
View/download PDF

5. Distinct determinants of muscle wasting in nonobese heart failure patients with and without type 2 diabetes mellitus

Author

Yano, Toshiyuki, primary, Katano, Satoshi, additional, Kouzu, Hidemichi, additional, Nagaoka, Ryohei, additional, Inoue, Takuya, additional, Takamura, Yuhei, additional, Ishigo, Tomoyuki, additional, Watanabe, Ayako, additional, Ohori, Katsuhiko, additional, Koyama, Masayuki, additional, Nagano, Nobutaka, additional, Fujito, Takefumi, additional, Nishikawa, Ryo, additional, Hashimoto, Akiyoshi, additional, and Miura, Tetsuji, additional

Published
2020
Full Text
View/download PDF

6. Independent link between peripheral artery disease and muscle wasting in patients with heart failure

Author

Ohori, Katsuhiko, primary, Yano, Toshiyuki, additional, Katano, Satoshi, additional, Kouzu, Hidemichi, additional, Inoue, Takuya, additional, Takamura, Yuhei, additional, Nagaoka, Ryohei, additional, Ishigo, Tomoyuki, additional, Koyama, Masayuki, additional, Nagano, Nobutaka, additional, Fujito, Takefumi, additional, Nishikawa, Ryo, additional, and Miura, Tetsuji, additional

Published
2020
Full Text
View/download PDF

7. Overestimation of glomerular filtration rate by creatinine‐based equation in heart failure patients is predicted by a novel scoring system

Author

Ishigo, Tomoyuki, primary, Katano, Satoshi, additional, Yano, Toshiyuki, additional, Kouzu, Hidemichi, additional, Ohori, Katsuhiko, additional, Nakata, Hiromasa, additional, Nonoyama, Masatoshi, additional, Inoue, Takuya, additional, Takamura, Yuhei, additional, Nagaoka, Ryohei, additional, Kondo, Fuki, additional, Nakano, Keita, additional, Takada, Ryo, additional, Kitagawa, Manabu, additional, Kimyo, Tomoko, additional, and Miura, Tetsuji, additional

Published
2020
Full Text
View/download PDF

9. Comparison of the Treatment Persistence Among 4 Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: A 5-Year Retrospective Cohort Study.

Author

Aigami T, Ishigo T, Takada R, Yano T, Koyama M, Katano S, Fujii S, and Fukudo M

Subjects
Humans, Aged, Rivaroxaban therapeutic use, Dabigatran therapeutic use, Anticoagulants therapeutic use, Retrospective Studies, Pyridones therapeutic use, Administration, Oral, Atrial Fibrillation drug therapy, Atrial Fibrillation complications, Atrial Fibrillation epidemiology, Stroke
Abstract

Four direct oral anticoagulants (DOACs) are used in Japan (edoxaban, rivaroxaban, apixaban, and dabigatran); however, few studies have examined the long-term treatment persistence of these DOACs. Furthermore, the factors associated with persistence remain unclear. This single-center, retrospective cohort study enrolled participants who were newly prescribed the 4 DOACs between January 1, 2012, and April 30, 2020. We assessed the treatment persistence rate by calculating the cumulative incidence rate of prescription switch or discontinuation for 5 years from the initial prescription. The factors associated with persistence were examined using multivariate analysis. The edoxaban was used as a reference for comparison with the other DOACs. The persistence rate at 5 years was 52.9% for all DOACs, including 67.0%, 51.6%, 50.2%, and 37.0% for edoxaban, rivaroxaban, apixaban, and dabigatran, respectively. Multivariate analysis revealed that age >65 years (hazard ratio [HR], 0.62 [95%CI, 0.41-0.93]), chronic kidney disease (HR, 1.63 [95%CI, 1.11-2.39]), baseline hemoglobin (HR, 0.85 [95%CI, 0.78-0.93]), diabetes mellitus (HR, 0.51 [95%CI, 0.29-0.93]), and type of DOACs (rivaroxaban: HR, 1.81 [95%CI, 1.03-3.18]; apixaban: HR, 2.00 [95%CI, 1.15-3.48]; and dabigatran: HR, 2.84 [95%CI, 1.66-4.86]) were significantly associated with nonpersistence at 1 year. At 5 years, diabetes mellitus (HR, 0.60 [95%CI, 0.37-0.97]) and type of DOAC were significantly associated with nonpersistence (rivaroxaban: HR, 1.79 [95%CI, 1.09-2.94]; apixaban: HR, 2.04 [95%CI, 1.26-3.31]; and dabigatran: HR, 2.76 [1.73-4.42]). Long-term treatment persistence differed according to the type of DOAC, with edoxaban exhibiting the highest level of persistence. The factors associated with persistence may change over the treatment course, but larger studies are required to generalize our findings., (© 2023, The American College of Clinical Pharmacology.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results